On Tuesday, Aug. 14, scPharmaceuticals (SCPH) presented its quarterly update, reporting a net loss of $9.9 million in Q2 - just better than analyst predictions. That said, the company still has a strong cash position of $101 million, which management believes is enough to finance operations through the end of 2019. Most importantly, SCPH has scheduled a Type A Meeting with the FDA on September 24, and the outcome of this meeting will determine the company's next steps.
Clinical Summary
SCPH's lead drug candidate, Furoscix, is a first-in-class subcutaneous furosemide infusor designed to